Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, the Netherlands.
Departments of Pain Translational Symptoms Science and Anaesthesiology, School of Nursing and Medicine, University of Maryland Baltimore, Baltimore, Maryland, USA.
Psychother Psychosom. 2018;87(4):204-210. doi: 10.1159/000490354. Epub 2018 Jun 12.
Placebo and nocebo effects occur in clinical or laboratory medical contexts after administration of an inert treatment or as part of active treatments and are due to psychobiological mechanisms such as expectancies of the patient. Placebo and nocebo studies have evolved from predominantly methodological research into a far-reaching interdisciplinary field that is unravelling the neurobiological, behavioural and clinical underpinnings of these phenomena in a broad variety of medical conditions. As a consequence, there is an increasing demand from health professionals to develop expert recommendations about evidence-based and ethical use of placebo and nocebo effects for clinical practice.
A survey and interdisciplinary expert meeting by invitation was organized as part of the 1st Society for Interdisciplinary Placebo Studies (SIPS) conference in 2017. Twenty-nine internationally recognized placebo researchers participated.
There was consensus that maximizing placebo effects and minimizing nocebo effects should lead to better treatment outcomes with fewer side effects. Experts particularly agreed on the importance of informing patients about placebo and nocebo effects and training health professionals in patient-clinician communication to maximize placebo and minimize nocebo effects.
The current paper forms a first step towards developing evidence-based and ethical recommendations about the implications of placebo and nocebo research for medical practice, based on the current state of evidence and the consensus of experts. Future research might focus on how to implement these recommendations, including how to optimize conditions for educating patients about placebo and nocebo effects and providing training for the implementation in clinical practice.
在临床或实验室医学环境中,在给予无效治疗或作为有效治疗的一部分后,会出现安慰剂和反安慰剂效应,这是由于患者的期望等心理生物学机制所致。安慰剂和反安慰剂研究已经从主要的方法学研究发展成为一个广泛的跨学科领域,该领域正在揭示这些现象在广泛的各种医学病症中的神经生物学、行为和临床基础。因此,越来越多的卫生专业人员要求制定关于在临床实践中使用安慰剂和反安慰剂效应的循证和伦理方面的专家建议。
作为 2017 年第一届社会跨学科安慰剂研究协会(SIPS)会议的一部分,通过邀请组织了一项调查和跨学科专家会议。29 名国际公认的安慰剂研究人员参加了会议。
与会者一致认为,最大限度地发挥安慰剂效应和最小化反安慰剂效应应导致更好的治疗效果和更少的副作用。专家们特别同意告知患者安慰剂和反安慰剂效应的重要性,并对卫生专业人员进行医患沟通培训,以最大限度地发挥安慰剂效应并最小化反安慰剂效应。
本文件基于当前的证据状况和专家共识,为制定有关安慰剂和反安慰剂研究对医疗实践影响的循证和伦理建议迈出了第一步。未来的研究可能侧重于如何实施这些建议,包括如何优化教育患者了解安慰剂和反安慰剂效应的条件,并为在临床实践中的实施提供培训。